Wednesday, October 28, 2026
Data from SEC filings, checked daily
Public filings, plainly told
AboutMethodSourcesNewsletter
StockCIK 1099800

Edwards Lifesciences Corp (EW): Insider Trades and Fund Holdings

In the past 12 months, Edwards Lifesciences Corp insiders reported 0 open-market purchases worth $0 and 6 sales worth $3.40M; 2 of the sales were reported as made under a 10b5-1 trading plan.

0Insider buys, 12 months
$0Bought by insiders, 12 months
$3.40MSold by insiders, 12 months
2Tracked funds holding

Timeline: news and trades

Company filings (8-K), insider trades, notices of planned sales (Form 144) and fund moves in the past year, newest first.

  1. Oct 8, 2026Insider saleCVP, TAVR Daniel J. Lippis sold $53,017 under a 10b5-1 plan
  2. Sep 11, 2026Insider saleCVP, TAVR Daniel J. Lippis sold $54,169 under a 10b5-1 plan
  3. Aug 31, 2026Insider saleSVP Andrew M. Dahl sold $49,534
  4. Aug 28, 2026Insider saleCVP, EMEACLA Annette Bruls sold $237,907
  5. Aug 26, 2026Insider saleCVP, TMTT, Surgical & IHFM Daveen Chopra sold $2.9 million
  6. Aug 26, 2026Insider saleCVP, JAPAC Wayne Markowitz sold $113,417
  7. Jun 30, 2026FundBridgewater Associates added 60% in Q2 2026 (13F filed Aug 14, 2026)
  8. Jun 30, 2026FundViking Global Investors sold out in Q2 2026 (13F filed Aug 14, 2026)
  9. Jun 30, 2026FundRenaissance Technologies cut 28% in Q2 2026 (13F filed Aug 13, 2026)

Recent insider trades

Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Oct 8, 2026.

Recent EW insider trades
FiledTradedInsiderRoleTypeSharesPrice ($)ValueHoldingFiling
Oct 8Oct 8Daniel J. LippisCVP, TAVRCVP, TAVR▼ SELL10b5-161985.65$53K−1.5%Form 4 ↗
Sep 11Sep 11Daniel J. LippisCVP, TAVRCVP, TAVR▼ SELL10b5-161987.51$54K−1.5%Form 4 ↗
Aug 31Aug 31Andrew M. DahlSVPSVP▼ SELL54491.06$50K−3.5%Form 4 ↗
Aug 28Aug 28Annette BrulsCVP, EMEACLACVP, EMEACLA▼ SELL2,64489.98$238K−13%Form 4 ↗
Aug 26Aug 26Daveen ChopraCVP, TMTT, Surgical & IHFMCVP, TMTT, Surgical & IHFM▼ SELL31,80091.02$2.89M−42%Form 4 ↗
Aug 26Aug 26Wayne MarkowitzCVP, JAPACCVP, JAPAC▼ SELL1,24091.47$113K−5.8%Form 4 ↗
Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings

Insiders who traded in the past year

InsiderRoleBuysBoughtSellsSoldLatest
Daniel J. LippisCVP, TAVR0$02$107KOct 8, 2026
Andrew M. DahlSVP0$01$50KAug 31, 2026
Annette BrulsCVP, EMEACLA0$01$238KAug 28, 2026
Daveen ChopraCVP, TMTT, Surgical & IHFM0$01$2.89MAug 26, 2026
Wayne MarkowitzCVP, JAPAC0$01$113KAug 26, 2026

Buybacks and executive pay

Edwards Lifesciences Corp spent $893.4 million buying back its own shares in 2025.

From the company's XBRL data filed with the SEC. "Actually paid" is the SEC's pay-versus-performance measure, which counts changes in the value of stock awards. "Value of $100 invested" is the company's cumulative shareholder return as reported, usually measured from five years earlier. See all buybacks and CEO pay across companies.

Tracked funds that report EW

From each fund's latest 13F. Holdings are as of quarter end and are filed up to 45 days later.

FundQuarterSharesValue% of portfolioChange
Bridgewater AssociatesQ2 2026275,279$24.9M0.10%▲ +60.1%
Renaissance TechnologiesQ2 202621,000$1.90M0.00%▼ −27.6%
Viking Global InvestorsQ2 20260$00.00%▼ Sold out
Source: SEC Form 13F-HR filings, retrieved Oct 28, 2026. How we read filings

Reading these numbers

Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →